Multicomponent verification of diagnosis in premature ovarian failure: A retrospective study

Cover Page

Cite item

Full Text

Abstract

Introduction. Premature ovarian failure (POF) is a loss of ovarian function in women under the age of 40 years.

Aim. To describe the multicomponent manifestations when verifying the diagnosis of POF using the assessment of the vaginal component in patients.

Materials and methods. We conducted a retrospective analysis of medical records from patients aged 35–40 years receiving outpatient care, divided into two groups. The test group included 38 patients with an irregular menstrual cycle (MC) with its duration more than 38 days (or the frequency of menstruation is less than 10 per year), followed by the absence of menstruation for 3 months (amenorrhea). The comparison group included 38 patients with regular MC who attended an outpatient preconception examination.

Results. Patients with POF, in addition to vasomotor symptoms and psycho-emotional disorders, have manifestations of hypoestrogenism, including symptoms of genitourinary syndrome/vulvovaginal atrophy. The concentration of Lactobacilli in the vaginal biotope in patients with POF was below the reference values (p < 0.001). In contrast, the concentration of facultative anaerobic (p < 0.001) and obligate anaerobic (p < 0.001) microorganisms, yeast-like fungi (p < 0.001), and representatives of the Mollicutes class (p < 0.001) exceeded the reference range. Therefore, the prevalence of the vagina, cervix, and vulva diseases (aerobic vaginitis, bacterial vaginosis, vulvovaginal candidiasis), for which patients with POF had 2 to 3 outpatient visits per year, was significantly higher than in patients with normal MC (p < 0.001; p < 0.001; p < 0.01). The relative risks in patients with POF were 4.3 for aerobic vaginitis, 12.1 for bacterial vaginosis, and 2.3 for vulvovaginal candidiasis.

Conclusion. The study highlights that gynecologists should recognize patients with POF may experience symptoms of genitourinary syndrome/vulvovaginal atrophy, not just vasomotor symptoms and psycho-emotional disorders, even if active vaginal symptoms are absent.

About the authors

Tatiana Y. Pestrikova

Far Eastern State Medical University

Author for correspondence.
Email: typ50@rambler.ru
ORCID iD: 0000-0003-0219-3400

D. Sci. (Med.), Prof.

Russian Federation, Khabarovsk

Tatyana I. Yurasova

Far Eastern State Medical University

Email: typ50@rambler.ru
ORCID iD: 0009-0003-9838-0557

Medical Resident

Russian Federation, Khabarovsk

References

  1. Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101823. doi: 10.1016/j.beem.2023.101823
  2. Moustaki M, Kontogeorgi A, Tsangkalova G, et al. Biological therapies for premature ovarian insufficiency: what is the evidence? Front Reprod Health. 2023;5:1194575. doi: 10.3389/frph.2023.1194575
  3. European IVF-monitoring Consortium (EIM), European Society of Human Reproduction and Embryology (ESHRE); CalhazJorge C, De Geyter C, Kupka MS, et al. Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Hum Reprod. 2017;32(10):1957-73. doi: 10.1093/humrep/dex264
  4. Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36(11):2207-15. doi: 10.1007/s10815-019-01572-0
  5. Li M, Zhu Y, Wei J, et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95-102. doi: 10.1080/13697137.2022.2153033
  6. Rudnicka E, Kruszewska J, Klicka K, et al. Premature ovarian insufficiency – aetiopathology, epidemiology, and diagnostic evaluation. Prz Menopauzalny. 2018;17(3):105-8. doi: 10.5114/pm.2018.78550
  7. Mishra GD, Davies MC, Hillman S, et al. Optimising health after early menopause. Lancet. 2024;403(10430):958-68. doi: 10.1016/S0140-6736(23)02800-3
  8. Салимова М.Д., Наделяева Я.Г. Преждевременная недостаточность яичников в популяционной выборке женщин Прибайкальского региона: распространенность и возрастные особенности. Acta Biomedica Scientifica. 2020;5(6):37-41 [Salimova MD, Nadelyaeva YaG. Premature ovarian failure in a population sample of women from the Baikal region: prevalence and age characteristics. Acta Biomedica Scientifica. 2020;5(6): 37-41 (in Russian)]. doi: 10.29413/ABS.2020-5.6.4
  9. Антонюк М.В., Новгородцева Т.П., Денисенко Ю.К., и др. Метаболический синдром. Актуальные вопросы диагностики, патогенеза и восстановительного лечения. Владивостокский филиал ДНЦ ФПД – НИИМКВЛ. Владивосток: Изд-во Дальневосточного федерального университета, 2018 [Antonyuk MV, Novgorodtseva TP, Denisenko YuK, et al. Metabolicheskii sindrom. Aktualnye voprosy diagnostiki, patogeneza i vosstanovitelnogo lecheniia. Vladivostok branch of the DNC FPD – NIIMKVL. Vladivostok: Publishing house of the Far Eastern Federal University, 2018 (in Russian)].
  10. Аполихина И.А., Горбунова Е.А. Лечение генитоуринарного синдрома в менопаузе: результаты опроса акушеров-гинекологов в России. Медицинский совет. 2017;13:157-64 [Apolikhina IA, Gorbunova EA. Treatment of genitourinary syndrome in menopause: results of a survey of obstetricians-gynecologists in Russia. Medical Council. 2017;13:157-64 (in Russian)]. doi: 10.21518/2079-701X-2017-13-157-164
  11. Maksimovic Celicanin M, Haahr T, Humaidan P, Skafte-Holm A. Vaginal dysbiosis – the association with reproductive outcomes in IVF patients: a systematic review and meta-analysis. Curr Opin Obstet Gynecol. 2024;36(3):155-64. doi: 10.1097/GCO.0000000000000953
  12. Väinämö S, Saqib S, Kalliala I, et al. Longitudinal analysis of vaginal microbiota during IVF fresh embryo transfer and in early pregnancy. Microbiol Spectr. 2023;11(6):e0165023. doi: 10.1128/spectrum.01650-23
  13. Garmendia JV, De Sanctis CV, Hajduch M, De Sanctis JB. Microbiota and Recurrent Pregnancy Loss (RPL); More than a Simple Connection. Microorganisms. 2024;12(8):1641. doi: 10.3390/microorganisms12081641
  14. Tian Q, Jin S, Zhang G, et al. Assessing vaginal microbiome through Vaginal Microecology Evaluation System as a predictor for in vitro fertilization outcomes: a retrospective study. Front Endocrinol (Lausanne). 2024;15:1380187. doi: 10.3389/fendo.2024.1380187
  15. Thomas HN, Neal-Perry GS, Hess R. Female Sexual Function at Midlife and Beyond. Obstet Gynecol Clin North Am. 2018;45(4):709-22. doi: 10.1016/j.ogc.2018.07.013
  16. Пестрикова Т.Ю., Швеева М.А., Юрасова Е.А., Веселкова Е.Г. Генитоуринальный менопаузальный синдромом: возможности локальной комбинированной терапии. Вопросы гинекологии, акушерства и перинатологии. 2024;23(1):123-30 [Pestrikova TYu, Shveeva MA, Yurasova EA, Veselkova EG. Genitourinary menopausal syndrome: possibilities of local combination therapy. Issues of Gynecology, Obstetrics and Perinatology. 2024;23(1):123-30 (in Russian)]. doi: 10.20953/1726-1678-2024-1-123-130

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).